Fig. 1
From: Chimeric antigen receptor T-cell therapy for relapsed and refractory thyroid cancer
Expansion of Chimeric Antigen Receptor T Cells In Vivo. A An overview of the treatment and monitoring of the patient from day − 8 to day 141. CAR-T cells were delivered through intravenous infusion on day 0. The dose of conditioning chemotherapy was fludarabine (30 mg/kg/day) plus cyclophosphamide (300 mg/kg/day). PET-CT, positron-emission tomography-computed tomography. B Changes in maximum body temperature per 24-h period. C The levels of CAR-T cells quantified by flow cytometry (left) and quantitative real-time polymerase-chain-reaction (center) from day 1 to day 137 after infusion. The y axes of these panels are log10 scales. D The dynamic changes of cytokines interleukin-6 and10, interferon-γ, and granzyme B